By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion Pharmaceuticals Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Acadia (ACAD) To Present At The JMP Securities Life Sciences Conference On June 21, 2016 6/16/2016 10:19:44 AM
Acadia (ACAD) To Present At The Goldman, Sachs & Co. 37th Annual Global Healthcare Conference On June 8, 2016 6/1/2016 4:49:35 PM
Acadia (ACAD) Announces NUPLAZID (Pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson’s Disease Psychosis 5/31/2016 10:52:08 AM
Acadia (ACAD) Drug Approval May Make It an Attractive Target for Biogen (BIIB), Teva (TEVA) 5/9/2016 7:02:18 AM
Acadia (ACAD) Reports First Quarter 2016 Financial Results 5/6/2016 9:05:25 AM
Acadia (ACAD) To Present At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference On May 11, 2016 5/4/2016 11:02:17 AM
Acadia (ACAD) To Announce First Quarter 2016 Financial Results On May 5, 2016 5/3/2016 10:54:29 AM
FDA Clears Acadia (ACAD)'s NUPLAZID, the First Drug for Psychosis Linked to Parkinson's 5/2/2016 6:08:55 AM
Acadia (ACAD) To Present At The 15th Annual Needham Healthcare Conference On April 12, 2016 4/6/2016 9:46:05 AM
Why SoCal's Acadia (ACAD) May Be a Perfect Takeover Target for Biogen (BIIB) 4/4/2016 6:57:09 AM